China bears the largest global burden of lung cancer, with a striking 40% of cases occurring in individuals who have never smoked.
While the mortality-reducing benefits of low-dose computed tomography (LDCT) for lung cancer screening are established, the quest for an optimal screening strategy continues, considering the potential adverse effects of LDCT.
The Chinese NCC-LCm2021 model was developed based on a nationwide population to identify at-risk individuals among smokers and nonsmokers.
However, the cost-effectiveness of this model has yet to be determined.
